Biotechnology

Filter

Current filters:

None

Popular Filters

1890 to 1914 of 2383 results

CytoDyn to acquire Progenics' PRO 140

31-07-2012

Development-stage biotech firm CytoDyn (OTCQB: CYDY), has entered into a asset purchase agreement with…

Anti-viralsBiotechnologyCytoDynCytolinPRO 140Progenics Pharmaceuticals

EMA increases interaction with Japanese regulators

30-07-2012

The European Medicines Agency has increased its level of interaction and cooperation with medicines regulatory…

Asia-PacificBiotechnologyEuropePharmaceuticalRare diseasesRegulation

New Zealand pharma urged to capturing value from innovation

30-07-2012

New Zealand's innovative companies and research community must protect their breakthroughs, for the country…

Asia-PacificBiotechnologyPatentsPharmaceuticalResearch

Genentech gains FDA panel backing for Lucentis to treat DME

30-07-2012

US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX), revealed last week that…

BiotechnologyGenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

US FDA clears Amarin's Vascepa, a competitor for Lovaza

30-07-2012

The US Food and Drug Administration has approved biotech firm Amarin's (Nasdaq: AMRN) Vascepa (icosapent…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLovazaMergers & AcquisitionsNorth AmericaRegulationVascepa

Gilead Sciences' 2nd-qtr beats consensus expectations

29-07-2012

US biotech firm Gilead Sciences (Nasdaq: GILD), the world's largest marketer of HIV/AIDS drugs, on Friday…

BiotechnologyFinancialGilead Sciences

FDA advisory panel backs approval of ThromboGenics' ocriplasmin for VMA

29-07-2012

Belgian biopharmaceutical firm ThromboGenics NV (Euronext Brussels: THR) says that the US Food and Drug…

AlconBiotechnologyNorth AmericaNovartisocriplasminOphthalmicsRegulationThromboGenics

Roche first-half sales and profits beat consensus forecasts

27-07-2012

Roche first-half sales and profits beat consensus forecasts

BiotechnologyFinancialPharmaceuticalRoche

Sanofi 2nd-qtr hit by Plavix competition but group sales still up 6%

27-07-2012

French pharma major Sanofi (Euronext: SAN) reported second-quarter 2012 financial results with net sales…

BiotechnologyFinancialGenzymePharmaceuticalSanofi

Amgen beats expectations as 2nd-qtr revenues rise 13% and EPS grows 34%

27-07-2012

The world's largest independent biotech company, USA-based Amgen (Nasdaq: AMGN), saw its shares move…

AmgenBiotechnologyFinancial

Global pharmaceutical approvals moderate as patent cliff peaks, says Fitch

26-07-2012

The Food and Drug Administration will approve fewer novel drugs in 2012 compared to 2011 while the industry…

BiotechnologyNorth AmericaPatentsPharmaceuticalRegulation

Batch of clinical trial results for Gilead's elvitegravir, Complera and cobicistat

25-07-2012

US biotech firm Gilead Sciences (Nasdaq: GILD), the world's biggest producer of HIV treatments, announced…

Anti-viralsBiotechnologycobicistatCompleraelvitegravirGilead SciencesResearch

Sarepta's shares rocket on positive results with eteplirsen in Duchenne muscular dystrophy

25-07-2012

US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) saw its shares leap 140% to $8.30 yesterday…

AVI BioPharmaBiotechnologyeteplirsenRare diseasesResearchSarepta Therapeutics

UK's NICE to takeover role of assessing high-cost rare disease drugs

25-07-2012

In the UK, the role of assessing very high cost drugs for people who suffer with rare conditions, under…

BiotechnologyEuropePharmaceuticalPricingRare diseasesRegulation

Biogen Idec 2nd-qtr sales and earnings top analysts expectations

25-07-2012

US biotech firm Biogen (Nasdaq: BIIB) pleased markets with its second-quarter 2012 financial results,…

Biogen IdecBiotechnologyFinancial

Pharma industry calls for broad-based cooperation to fight on-line sales of counterfeit medicines

24-07-2012

The global pharmaceutical industry unveiled recommendations this week to tackle the growing public health…

BiotechnologyGenericsGlobalMarkets & MarketingPharmaceuticalRegulation

US govt plans innovative public-private partnerships to turn the tide in fight against HIV/AIDS

23-07-2012

In a speech at the opening session of the XIX International AIDS Conference (AIDS 2012) in Washington…

Anti-viralsBiotechnologyHealthcareNorth AmericaPharmaceutical

Onyx soars as FDA approves Kyprolis for multiple myeloma

23-07-2012

Shares of US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) leapt 11.7% to $76.38 on Friday, after…

BiotechnologyKyprolisNorth AmericaOncologyOnyx PharmaceuticalsRegulation

Synergy Pharma and Callisto enter merger accord

22-07-2012

USA-based biopharma groups Synergy Pharmaceuticals (Nasdaq: SGYP) and Callisto Pharmaceuticals (OTCBB:…

BiotechnologyCallisto PharmaceuticalsMergers & AcquisitionsSynergy Pharmaceuticals

Barriers to overcome in lupus drug development

22-07-2012

It has taken the lupus research community over 50 years to produce a new therapy. Although it is now…

Anthera PharmaceuticalsBenlystaBiotechnologyblisibimodGlaxoSmithKlineImmunologicalsPharmaceuticalResearch

Actelion hikes earnings outlook despite lower sales

20-07-2012

Switzerland-based Actelion (ATLN: VX), Europe's largest biotech company, reported first-half 2012 financial…

ActelionBiotechnologyFinancial

Pharmaceutical supply chain in Japan sees squeezed margins

19-07-2012

Pressures felt in Japan as a result of the country's aging population, drug price revisions and patent…

Asia-PacificBiotechnologyFinancialMarkets & MarketingMergers & AcquisitionsPharmaceuticalPricing

1890 to 1914 of 2383 results

Parexel

Parexel

Back to top